Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesRefractory anemia with ring sideroblasts and RARS with thrombocytosisGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Ruxolitinib: A Review in Polycythaemia Vera.Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.Experience with ruxolitinib in the treatment of polycythaemia vera.Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case reportDisordered haematopoiesis and athero-thrombosis.Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon.Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice.Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Molecular genetic evaluation of myeloproliferative neoplasms.Ruxolitinib for the treatment of patients with polycythemia vera.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera.Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment.Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM.Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.The Epimmunity Theory: The Single Cell Defenses against Infectious and Genetic Diseases.Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center.Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.Essential thrombocythemia: Busulphan revisited.Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsRecurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy.From anemia to polycythemia in 4 weeks.Persistent Reactive Thrombocytosis May Increase the Risk of Coronary Artery Disease Among Inflammatory Bowel Disease Patients.Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations.
P2860
Q26775996-369BBFBE-C868-496A-8A90-8BEE12DE0CBEQ28083238-BF607149-9501-4C07-BA66-D614D8E64203Q30276550-72DD0FB6-C85F-427C-82F7-BBB5C00EC537Q33425781-E8F928DB-BD27-4057-A356-A5EE3DBDB3F9Q33439747-8AAFC843-DF1D-4116-B9E5-45D6330F5ED6Q33605624-AE0F40D9-775C-4B12-B6D3-A6A018B42D2AQ33747797-30D1FCA7-904F-4CF4-B316-495FD4B75BC9Q36524740-49500847-F559-46C5-B44F-BA9250BFDA2BQ36773876-D3476BDF-98ED-4CC9-8814-B1457F2C8F5FQ37048533-D4DFA1D4-AFBB-45B0-9ADA-47356A6B06C6Q37328478-BBF9F3A8-C59D-405E-88F9-356CAEB440A3Q37372104-3BA29285-306C-4872-8009-FF8F6E71C51AQ37638779-BBAEA909-4EB7-4844-BA73-115D4843B168Q38481945-A7F1751B-09B8-4C85-B986-D5B9939BB0A9Q38484321-035134FE-7383-4F00-861B-3B6F1AF82D1CQ38586505-9A27E58C-94A2-4879-9459-88799797D410Q38613880-D0F61F1F-4AAA-4829-80CB-0EFBDAB31BA8Q38740700-C013ECCF-242F-4CDD-99D1-AAD407399A76Q38771057-8947F11A-E961-4E0B-AA2E-FE838D0FCB73Q38802882-B4324CB0-4AC4-4EF5-8CCD-FCACB529AAB4Q38815464-F71BED97-D9EC-4632-8C0F-5D685D027048Q38842371-88846001-F14C-4630-A172-05ADE1D08284Q38917400-6D60FFF7-06FB-47D7-991B-6CA9E65A7FA6Q38918874-721165A1-906A-4401-AEB5-EECE887B4A52Q38939571-D6CF8446-98A6-4AEF-B2BF-F989A94FA6E8Q39131365-2B9A5271-F99D-4E0D-B1F2-8600A0F7E2D9Q39456996-9F182F59-6AFB-4B13-87BE-37B0460E3FC0Q39661740-A0D4125F-FE0E-45B4-8328-6C37BCC23EF2Q39869975-CA447251-9622-453A-8677-A2380D0D0A11Q40154111-26B48E4A-9756-4938-80E5-5663D218A14FQ40465954-C9BF198C-28C8-4DB2-9DF1-3EF8730E6DEDQ40544279-DDD559EB-DB3B-441C-BF20-E526665B57B3Q40555261-F09CB7DA-BD66-40EC-8131-230273FCB6D9Q40906382-67CB4711-9BD4-44DC-AD63-14E33E9F53DCQ41217822-539061A7-5D4D-4DB8-B091-21F95CCC8B84Q41510435-635C3839-5154-47AB-A58E-D6C8F19CA59CQ41553988-D414690F-C568-45DA-8ACB-9650C78FCC2CQ41599861-9ED603E1-291B-4EEF-8EB3-47B9F2443575Q41740125-B4BC9711-AE8A-453E-8DB0-A48119DF0AB8Q41956352-D918D219-BCB2-4340-A9B1-3B7422ABE0A3
P2860
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Polycythemia vera and essentia ...... -stratification and management
@ast
Polycythemia vera and essentia ...... -stratification and management
@en
Polycythemia vera and essentia ...... -stratification and management
@nl
type
label
Polycythemia vera and essentia ...... -stratification and management
@ast
Polycythemia vera and essentia ...... -stratification and management
@en
Polycythemia vera and essentia ...... -stratification and management
@nl
prefLabel
Polycythemia vera and essentia ...... -stratification and management
@ast
Polycythemia vera and essentia ...... -stratification and management
@en
Polycythemia vera and essentia ...... -stratification and management
@nl
P2860
P3181
P356
P1476
Polycythemia vera and essentia ...... -stratification and management
@en
P2093
Tiziano Barbui
P2860
P304
P3181
P356
10.1002/AJH.23895
P407
P577
2015-02-01T00:00:00Z